Aimery de Gramont

Summary

Country: France

Publications

  1. ncbi Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors
    Pierre Blanchard
    Service d Oncologie Medicale, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75012, Paris, France
    Gynecol Oncol 104:41-5. 2007
  2. doi Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
    Aimery de Gramont
    Hopital Saint Antoine, Paris, France
    Lancet Oncol 13:1225-33. 2012
  3. doi The evolution of adjuvant therapy in the treatment of early-stage colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 10:218-26. 2011
  4. ncbi Rapid evolution in colorectal cancer: therapy now and over the next five years
    Aimery de Gramont
    Hopital Saint Antoine, 184 Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 10:4-8. 2005
  5. ncbi First-line therapy for advanced colorectal cancer
    Aimery de Gramont
    Service de médecine interne oncologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    Curr Oncol Rep 7:167-72. 2005
  6. ncbi Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer
    Aimery de Gramont
    Hopital Saint Antoine, Paris Cedex 12, France
    J Clin Oncol 25:3224-9. 2007
  7. doi From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Semin Oncol 38:521-32. 2011
  8. ncbi Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
    Anne Marie Coudray
    INSERM U482, Signal Transduction and Cellular Functions in Diabetes and Digestive Cancers, Paris, France
    Int J Oncol 27:553-61. 2005
  9. doi Platinum-sensitivity in metastatic colorectal cancer: towards a definition
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, APHP, Paris, France Université Pierre et Marie Curie, Universite Paris 6, Paris, France GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie, Paris, France Electronic address
    Eur J Cancer 49:3813-20. 2013
  10. doi Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study
    Benoist Chibaudel
    Hopital Saint Antoine, Paris Cedex 12, France
    J Clin Oncol 27:5727-33. 2009

Detail Information

Publications65

  1. ncbi Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors
    Pierre Blanchard
    Service d Oncologie Medicale, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75012, Paris, France
    Gynecol Oncol 104:41-5. 2007
    ..Relapses of epithelial ovarian carcinoma (EOC) have a poor prognosis. Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy...
  2. doi Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
    Aimery de Gramont
    Hopital Saint Antoine, Paris, France
    Lancet Oncol 13:1225-33. 2012
    ..Our aim was to assess the use of bevacizumab in combination with oxaliplatin-based chemotherapy in the adjuvant treatment of patients with resected stage III or high-risk stage II colon carcinoma...
  3. doi The evolution of adjuvant therapy in the treatment of early-stage colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 10:218-26. 2011
    ..The synthesis of these data allows us to conceive a future development focused on translational research...
  4. ncbi Rapid evolution in colorectal cancer: therapy now and over the next five years
    Aimery de Gramont
    Hopital Saint Antoine, 184 Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 10:4-8. 2005
    ..South San Francisco, CA, http://www.gene.com), and on the ability of applied genomics to distinguish between high- and low-risk populations...
  5. ncbi First-line therapy for advanced colorectal cancer
    Aimery de Gramont
    Service de médecine interne oncologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    Curr Oncol Rep 7:167-72. 2005
    ..Furthermore, we fear that limited financial resources will also influence the management of this disease...
  6. ncbi Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer
    Aimery de Gramont
    Hopital Saint Antoine, Paris Cedex 12, France
    J Clin Oncol 25:3224-9. 2007
    ....
  7. doi From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Semin Oncol 38:521-32. 2011
    ..Clarity regarding the clinical signal needed before launching a phase III study and optimized designs adapted to multiple agents are urgently needed for new trials...
  8. ncbi Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
    Anne Marie Coudray
    INSERM U482, Signal Transduction and Cellular Functions in Diabetes and Digestive Cancers, Paris, France
    Int J Oncol 27:553-61. 2005
    ..These encouraging results warrant further preclinical investigations and clinical trials on the use of BGC9331 combined with SN-38/CPT-11 in treatment of patients with advanced colorectal or gastric cancers...
  9. doi Platinum-sensitivity in metastatic colorectal cancer: towards a definition
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, APHP, Paris, France Université Pierre et Marie Curie, Universite Paris 6, Paris, France GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie, Paris, France Electronic address
    Eur J Cancer 49:3813-20. 2013
    ..Influence of the first-line oxaliplatin-based treatment efficacy and the duration of OFI on tumour sensitivity to oxaliplatin reintroduction were investigated...
  10. doi Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study
    Benoist Chibaudel
    Hopital Saint Antoine, Paris Cedex 12, France
    J Clin Oncol 27:5727-33. 2009
    ....
  11. ncbi OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, Paris, France
    J Clin Oncol 24:394-400. 2006
    ..This study evaluates a new strategy of intermittent oxaliplatin treatment that is based on FOLFOX7, a simplified leucovorin and fluorouracil regimen with high-dose oxaliplatin...
  12. ncbi Adjuvant therapy for stage II and III colorectal cancer
    Aimery de Gramont
    Groupe Coopérateur Multidisciplinaire en Oncologie, Hopital Saint Antoine, Service de médecine interne oncologie, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Semin Oncol 34:S37-40. 2007
    ..Studies are ongoing to identify optimal adjuvant regimens in stage II or III disease and to identify the potential benefits of adding bevacizumab or cetuximab to adjuvant therapy...
  13. doi Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Tre
    Christophe Tournigand
    Hopital Saint Antoine, Paris, France
    J Clin Oncol 30:3353-60. 2012
    ..Oxaliplatin combined with fluoropyrimidine improves survival in patients with stage III colon cancer. However, adjuvant chemotherapy with oxaliplatin is controversial in stage II and elderly patients...
  14. pmc Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
    Benoist Chibaudel
    Department of Medical Oncology, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 16:1228-38. 2011
    ..The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer...
  15. ncbi Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer
    May Mabro
    Department of Medical Oncology, Hopital Saint Antoine, Paris, France
    Am J Clin Oncol 26:254-8. 2003
    ..FOLFIRI-2 achieved a good rate of response and stabilization in heavily pretreated patients despite significant toxicity...
  16. doi Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study
    Benoist Chibaudel
    Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, 184, rue du Faubourg Saint Antoine, 75571, Paris Cedex 12, France
    J Clin Oncol 29:4199-204. 2011
    ..The goal of this study was to evaluate these alternative end points and their potential surrogacy for overall survival (OS)...
  17. doi Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1)
    Isabelle Baumgaertner
    Department of Hepatogastroenterology, Hopital Pitie Salpetriere, Paris, France
    Clin Colorectal Cancer 9:E5-10. 2010
    ..These analyses compare the safety and efficacy of 2 forms (levogyre [L] and dextro-levogyre [DL]) of leucovorin (LV) when used with 5-fluorouracil (5-FU) for the adjuvant treatment of patients with stage II and III colon cancer...
  18. ncbi FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    J Clin Oncol 22:229-37. 2004
    ..This phase III study investigated two sequences: folinic acid, FU, and irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin (FOLFOX6; arm A), and FOLFOX6 followed by FOLFIRI (arm B)...
  19. ncbi Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1
    Thierry Andre
    Public Hôpitaux de Paris and CancerEst, Hopital Tenon, Paris, France
    J Clin Oncol 25:3732-8. 2007
    ....
  20. ncbi Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
    Thierry Andre
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France
    J Clin Oncol 27:3109-16. 2009
    ..7% at 48 months. CONCLUSION Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease...
  21. ncbi Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission
    Christophe Tournigand
    Service d Oncologie Medicale, Hopital Saint Antoine, Paris, France
    Gynecol Oncol 91:341-5. 2003
    ....
  22. ncbi Pemetrexed in advanced colorectal cancer
    Christophe Louvet
    Hopital St Antoine, Service de Medecine Int Onc, Paris, France
    Oncology (Williston Park) 18:56-62. 2004
    ..All of these trials include vitamin supplementation. A phase III trial comparing the every-3-week pemetrexed/oxaliplatin regimen with FOLFOX4 as first-line treatment will be initiated if the outcome of the phase II trial is encouraging...
  23. ncbi Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients
    Frédérique Maindrault-Goebel
    Saint Antoine Hospital, Oncology Department, 184, rue du Saint Faubourg, Saint Antoine, 75571 Paris, Cedex 12, France
    Eur J Cancer 41:2262-7. 2005
    ..For the non-life-threatening reactions, prolonging infusion duration, "Stop and Go" regimen seem to be effective means of preventing recurrence...
  24. ncbi An overview of adjuvant systemic chemotherapy for colon cancer
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris, France
    Clin Colorectal Cancer 4:S22-8. 2004
    ..Future studies in adjuvant therapy for colon cancer will explore oxaliplatin and 5-FU with or without antiangiogenesis or anti-epidermal growth factor agents...
  25. ncbi Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells
    Eric Raymond
    INSERM U482, Hopital Saint Antoine, Paris, France
    Int J Oncol 21:361-7. 2002
    ..These results argue in favor of clinical trials of chemotherapy combining MTA with oxaliplatin or irinotecan (CPT-11), for the treatment of patients with colon cancer...
  26. ncbi Stage II and stage III colon cancer: treatment advances and future directions
    Benoit Rousseau
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, France
    Cancer J 16:202-9. 2010
    ..Adjuvant therapy in elderly patients is another matter of debate due to the lack of survival advantage in the recent trials...
  27. ncbi Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen)
    Christophe Louvet
    Service de médecine interne oncologie, Hopital St Antoine, 184 rue du fbg St Antonie, 75012, Paris, France
    Cancer Invest 21:14-20. 2003
    ..Response rate and survival in patients with gastric linitis or diffuse forms were in the same range as in patients with intestinal forms of gastric adenocarcinoma...
  28. doi EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies
    Virginie Poindessous
    Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint Antoine, Paris, France
    Clin Cancer Res 17:6522-30. 2011
    ..We speculated that inhibition of surface receptors and ligands might only partly prevent oncogenic signaling whereas small-molecule tyrosine kinase inhibitors (TKI) would also influence intracellular signaling...
  29. ncbi [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer]
    Christophe Tournigand
    Service d Oncologie Medicale, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12
    Bull Cancer 93:S11-5. 2006
    ..Combinations of capecitabine and oxaliplatine are also promising. The next step will come from the two new targeted therapies in metastatic colorectal cancer, directed against EGFR and VEGF...
  30. ncbi Current issues in adjuvant treatment of stage II colon cancer
    Thierry Andre
    Service d Oncologie Medicale, Hopital Tenon, 4 rue de la Chine, 75970, Paris Cedex 20, France, and Vall d Hebron University Hospital, Barcelona, Spain
    Ann Surg Oncol 13:887-98. 2006
    ..In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial...
  31. pmc Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set
    Aimery de Gramont
    Hopital Saint Antoine, Group Hospitalier Pitie Salpetriere, Paris, France
    J Clin Oncol 28:460-5. 2010
    ..New therapies have extended survival after recurrence from 1 to approximately 2 years. We examined the possible impact of this improvement on the DFS/OS association...
  32. ncbi Targeted agents for adjuvant therapy of colon cancer
    Aimery de Gramont
    GERCOR Groupe Coopérateur Multidisciplinaire en Oncologie and Hôpital Saint Antoine, Paris, France
    Semin Oncol 33:S42-5. 2006
    ..Cetuximab is being evaluated in combination with FOLFOX4 and FOLFOX6 in the North Central Cancer Treatment Group (NCCTG) N0147 trial and the Pan European Trials in Adjuvant Colon Cancer (PETTAC) 8 trial...
  33. ncbi [Management of metastatic colorectal cancer]
    Christophe Tournigand
    Service d Oncologie Medicale, Hopital Saint Antoine, 75571 Paris Cedex 12
    Rev Prat 60:1103-7. 2010
    ..Undoubtedly, advances in biology can both identify new targets, and therefore new treatments, but also better define patient groups most likely to get a benefit of these treatments...
  34. doi Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions
    Benoist Chibaudel
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Clin Colorectal Cancer 9:269-73. 2010
    ..A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are needed to design future adjuvant trials...
  35. doi Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy
    Aziz Zaanan
    Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, AP HP, Paris, France
    Clin Cancer Res 17:7470-8. 2011
    ..The aim of this study was to evaluate the prognostic value of MMR status for DFS in patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy...
  36. pmc Current status of adjuvant therapy for colon cancer
    Thierry Andre
    Hopital Tenon, Paris, France
    Gastrointest Cancer Res 1:90-7. 2007
    ..Duration of therapy and prevention of oxaliplatin neurotoxicity are other critical areas for future research...
  37. ncbi [Colon cancer: what is new in 2004?]
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris, France
    Bull Cancer 91:75-80. 2004
    ..Shrinkage of tumours after administration of preoperative chemotherapy and availability of ablative techniques (radiofrequency and cryotherapy) now allow to treat with curative intent metastases initially considered as non-resectable...
  38. ncbi Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer
    Aimery de Gramont
    Hopital Saint Antoine, Paris, France
    Oncology 69:46-56. 2005
    ..001). Bevacizumab has the potential to provide significant efficacy benefits for patients with metastatic RCC, NSCLC, pancreatic cancer, and other tumor types when used first line in combination with standard therapy...
  39. ncbi [Operable colon cancer: initial strategy]
    Thierry Andre
    Service d Hepato gastro enterologie, Groupe Hospitalier La Pitié Salpêtrière, AP HP, 75651 Paris Cedex 13
    Rev Prat 60:1089-93. 2010
    ..This treatment is not indicated in patients with stage-I tumor...
  40. ncbi [Anti-angiogenic treatment and colorectal cancer]
    Thierry Andre
    Service d Oncologie Medicale, Hopital Tenon, 4, rue de la Chine, 75970 Paris Cedex 20
    Bull Cancer 94:S211-9. 2007
    ..Several questions regarding the optimal use of bevacizumab still remain to be answered in the treatment of metastastic colorectal cancer. Vatalanib has not shown benefit in this pathology...
  41. ncbi Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
    Florence Huguet
    Department of Radiation Oncology, Tenon Hospital, Assistance Publique Hopitaux de Paris, France
    J Clin Oncol 25:326-31. 2007
    ..The decision to administer CRT or continue CT in nonprogressive patients was the investigator's choice...
  42. ncbi Prognostic impact of positive surgical margins after resection of colorectal cancer liver metastases: reappraisal in the era of modern chemotherapy
    Hadrien Tranchart
    Department of Digestive Surgery, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75012, Paris, France
    World J Surg 37:2647-54. 2013
    ..R1 resection is a negative prognostic factor after LR of CRLM. The significance of R1 margins in the era of effective chemotherapy is unknown...
  43. pmc Therapeutic strategy in unresectable metastatic colorectal cancer
    Benoist Chibaudel
    Division of Medical Oncology, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, 184 rue du Faubourg Saint Antoine, 75571, Paris Cedex 12, France
    Ther Adv Med Oncol 4:75-89. 2012
    ..Alternative outcomes that can be measured earlier than overall survival are needed to shorten the duration and reduce the size and cost of clinical trials...
  44. doi Perivascular epithelioid cell tumor: the first malignant case report in the pancreas
    Najat Mourra
    Department of Pathology, Hopital Saint Antoine, 75012 Paris, France
    Appl Immunohistochem Mol Morphol 21:e1-4. 2013
    ..The patient developed liver metastases 6 months after surgery. Although mostly benign, thorough sampling of the PEComa is mandatory, to rule out malignant behavior whatever the location of the tumor is...
  45. ncbi Pemetrexed in patients with gastrointestinal carcinoma
    Aimery de Gramont
    Hopital Saint Antoine, Service de médecine interne oncologie, Paris, France
    Semin Oncol 29:42-9. 2002
    ....
  46. pmc Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
    Daniele Grazziotin Soares
    Group of Cancer Biology and Therapeutics, Institut National de la Sante et de la Recherche Medicale, Unite 673, and Universite Pierre et Marie Curie, Hopital Saint Antoine, 75571 Paris Cedex 12, France
    Proc Natl Acad Sci U S A 104:13062-7. 2007
    ..Because loss of repair proteins is common in human tumors, expression levels of selected repair factors may be useful in identifying patients particularly likely to benefit, or not, from treatment with ET-743...
  47. ncbi Colorectal cancer: integrating oxaliplatin
    Christophe Louvet
    Service d Oncologie, Hopital St Antoine, 184 rue du Faubourg St Antoine, 75012 Paris, France
    Curr Treat Options Oncol 4:405-11. 2003
    ..The tolerance of the oxaliplatin/5-FU combination allows for design regimens integrating new drugs, such as biologic modifiers...
  48. ncbi Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 25:5225-32. 2007
    ....
  49. ncbi [Adjuvant treatment of colon cancer MOSAIC study's main results]
    Thierry Andre
    Hopital Tenon, 4 rue de la Chine, 75970 Paris Cedex 20
    Bull Cancer 93:S5-9. 2006
    ..Based on the data currently available, physicians should consider adjuvant treatment for stage II patients, making each individual decision for treatment on a case-by-case basis...
  50. ncbi Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial
    Thierry Andre
    Hopital Tenon, Groupe d Etude et de Recherche Clinique en Oncologie Radioitherapie, Paris
    J Clin Oncol 21:2896-903. 2003
    ....
  51. ncbi [Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus]
    Pierre Nahon
    Gastroenterol Clin Biol 27:555-6. 2003
  52. ncbi Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
    Daniel J Sargent
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:8664-70. 2005
    ..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice...
  53. ncbi Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer
    Howard S Hochster
    Department of Medicine Clinical Pharmacology, New York University Cancer Institute, New York, New York, USA
    Cancer 107:676-85. 2006
    ..Other targeted therapies also are considered for future clinical trials. Based on a comprehensive review of past trials, a consensus on endpoints in the treatment of pancreatic cancer and an approach to new trials is presented...
  54. ncbi Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer
    J Philip Kuebler
    Riverside Methodist Hospital Cancer Services, Columbus, OH, USA
    Semin Oncol 30:40-6. 2003
    ..Other trials currently in progress attempt to identify whether these new chemotherapeutic regimens can improve survival in the adjuvant setting...
  55. ncbi [Adjuvant treatment of colorectal cancer]
    Carine Segura
    Hopital Tenon, 4, rue de la Chine, 75970 Paris, Cedex 20
    Bull Cancer 93:683-90. 2006
    ..Now studies evaluate the role of bevacizumab (Avant, NSABP C08) and cetuximab (Petacc 8 and NCCTG-N0147) in combination with Folfox4 in stage III tumors...
  56. ncbi FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study
    Arie Figer
    Beth Sourasky Medical Center Tel Aviv, Israel
    Cancer 110:2666-71. 2007
    ..An exploratory cohort of patients aged 76 to 80 years was included in the study...
  57. ncbi End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group
    Daniel J Sargent
    Department of Health Sciences Research, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:4569-74. 2007
    ..We previously validated disease-free survival (DFS) after 3-year follow-up as an excellent predictor of 5-year OS results. Here we explore shorter term DFS and OS end points, as well as stage dependency...
  58. ncbi Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study
    Julien Taieb
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    J Clin Oncol 23:502-9. 2005
    ..To evaluate the efficacy and tolerability of the metastatic irinotecan plus oxaliplatin (MIROX) strategy (adjuvant FOLFOX-7 followed by FOLFIRI), in patients with resectable metastatic colorectal cancer...
  59. ncbi Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Thierry Andre
    Hopital Tenon, Paris
    N Engl J Med 350:2343-51. 2004
    ..Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting...
  60. doi Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy
    Laurence Gamelin
    J Clin Oncol 26:1188-9; author reply 1189-90. 2008
  61. ncbi Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study)
    Mohamed Hebbar
    Unité d Oncologie Médicale, Hôpital Huriez CHRU, Lille, France
    Cancer Invest 24:154-9. 2006
    ..1 percent). Median progression-free and overall survivals were 8.8 and 18.7 months, respectively. Only 2 patients (5.1 percent) had Grade 3 oxaliplatin-related sensory-neuropathy. This schedule had so promising efficacy and safety...
  62. ncbi Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
    Richard M Goldberg
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:4085-91. 2006
    ..This analysis compares the safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in patients age younger than and at least 70 years...
  63. pmc Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer
    Armelle Dufresne
    University Hospital E Herriot, Lyon, France
    Int J Med Sci 5:100-5. 2008
    ..0001; p = .001). The major impact obtained by maintenance hormonal treatment after first-line chemotherapy in this study seems to indicate that this strategy should be recommended in patients with an ER or PgR positive tumour...
  64. ncbi [Use of complementary medicine by cancer patients in a French oncology department]
    Stéphanie Träger-Maury
    Centre Hospitalier, avenue Paul Rougé, 60309 Senlis
    Bull Cancer 94:1017-25. 2007
    ..This warning could improve the confidence relationship between the oncologist and his patient...
  65. ncbi [A good cooperation between industry and French medical oncologists]
    Thierry Andre
    Bull Cancer 93:S3-4. 2006